Fresenius Puts Kabi At The Top As It Ponders Best Use Of Cash
‘Assume We Will Remain Sole Kabi Owner’ Under Potential Investments
Executive Summary
The Fresenius group has all but ruled out any equity investment in Fresenius Kabi, as it looks to make the best use of its capital and “tap new capital sources” to drive growth.
You may also be interested in...
What’s Next? Five Things To Look Out For In October
A busy October will include planned biosimilar launches and key appointments for the off-patent sector.
Kabi Urges Caution And Patience On Subcutaneous Bortezomib Launch
Fresenius Kabi’s Q1 call spanned its recent launch of a generic version of Takeda’s Velcade subcutaneous injectable to the company’s continued ambitions in biosimilars, with the German firm’s acquisition of a controlling stake in mAbxience scheduled to close by the middle of the year.
Fresenius Kabi Acquires Ivenix For $240M To Expand Presence In Infusion Pump Market
Fresenius Kabi will pay up to $240m for Massachusetts-based Invenix to expand its infusion pump portfolio. Simultaneously, the company also made a major move to bolster its biosimilars business by acquiring a majority stake in mAbxience.